BCMA CAR-T Therapy with Gamma-Secretase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for treating autoimmune diseases and cancers, such as multiple myeloma, are limited by low expression of BCMA on tumor cells and soluble BCMA in circulation, which reduces the efficacy of therapeutic agents by limiting binding and leading to cancer cell escape.
Innovation Solution
Development of BCMA-specific chimeric antigen receptor (CAR) molecules with enhanced spacer regions and γ-secretase inhibitors to increase BCMA surface expression on tumor cells, combined with BCMA-specific binding proteins and γ-secretase inhibitors for improved immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCMA-specific therapeutic agents are used to treat cancer, then tumor cells expressing BCMA can be targeted, but low BCMA surface expression and soluble BCMA in circulation limit binding efficacy and enable cancer cell escape
Solution Approach 1:
The patent employs γ-secretase inhibitors to alter the proteolytic cleavage parameter of BCMA, preventing shedding and increasing surface expression. This parameter change in BCMA stability directly addresses the low surface expression problem and improves therapeutic agent binding efficacy
Solution Approach 2:
The patent introduces γ-secretase inhibitors as intermediary agents that block the enzymatic cleavage of BCMA. This intermediary intervention prevents the formation of soluble BCMA and maintains membrane-bound BCMA, thereby enhancing the effectiveness of BCMA-specific therapeutic agents
2Reliability
If γ-secretase inhibitors are used to increase BCMA surface expression, then binding efficacy of therapeutic agents is improved, but off-target effects on other γ-secretase substrates may occur
Solution Approach 1:
The patent uses sub-inhibitory concentrations of γ-secretase inhibitors that are sufficient to increase BCMA surface expression but insufficient to cause significant off-target effects. This partial action approach achieves the desired BCMA stabilization while minimizing adverse effects on other γ-secretase substrates
Solution Approach 2:
The patent administers γ-secretase inhibitors prior to BCMA-specific therapeutic agents to pre-establish high BCMA surface expression. This preliminary action ensures optimal binding conditions are created before introducing the main therapeutic agent, potentially reducing the need for high doses of either agent
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the recognition and targeting of BCMA-positive cells by T cells, increasing cytokine production and cytolytic activity, and maintaining therapeutic efficacy even in the presence of soluble BCMA, thereby improving treatment outcomes for autoimmune diseases and cancers.
Implementation Method 1
γ-secretase inhibitors, which block the cleavage of BCMA from the cell surface
Implementation Method 2
BCMA-specific binding proteins, such as a chimeric antigen receptor (CAR), that specifically bind to BCMA
Implementation Method 3
increasing cytokine production and cytolytic activity
Data Source
AI summary
The present disclosure relates to methods for using BCMA-specific binding molecules (such as a BCMA-specific chimeric antigen receptor or antibody) in combination with γ-secretase inhibitors, which can be done concurrently or sequentially, to treat or prevent a B-cell related proliferative disease, such as a cancer or autoimmune disease, or the like. A BCMA-specific binding molecule in combination with γ-secretase inhibitor can be used in, for example, adoptive immunotherapy.